Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2004

View Archived Issues

Therapeutic benefits of statins in heart transplant patients

Levosimendan in intensive care

CpG ODN 1826 activates uveitogenic T-cells in mice

Regression of ocular neovascularization by periocular PEDF gene therapy

Antineoplastic effects of pioglitazone on malignant tumor growth in rat glioma model

NDA submission for Glumetza

Greater benefits found for calcium acetate in hemodialysis patients with hyperphosphatemia

Two novel CXCR2 antagonists and their use presented by AstraZeneca

New non-nucleoside HIV RT inhibitors identified at Boehringer Ingelheim

Lilly claims TGF-beta receptor kinase inhibitors for cancer and other disorders

Novel selective RARalpha ligands developed by Allergan researchers

Axys (Celera Genomics) patent covers new cathepsin B inhibitors for cancer, arthritis, etc.

New antiangiogenic agents in early development at Boehringer Ingelheim

Cognitive effects of SGS-742 in patients with mild cognitive impairment

Novel gamma-secretase inhibitor for Alzheimer's disease therapy

Tyrosine kinase inhibitor blocks choroidal neovascularization

PARP inhibition protects neurons and white matter from focal cerebral stroke

2'-FdC effective against Borna disease virus

Trehalose opens new approach to treatment of polyglutamine diseases

Celgene to stop Revlimid phase III trials in melanoma

Ceregene to advance Alzheimer's gene therapy

Genaissance amends license agreements for cardiac ion channel gene patents

GW Pharmaceuticals to submit more information for U.K. review of Sativex

Interim results for first phase III trial of AERx iDMS

Sepracor to phase out Astelin copromotion agreement with MedPointe

Abbott continues shift toward highly innovative business during Q1 2004

Genentech updates product development events during Q1 2004

Antigenics highlights Q1 developments

SPM-927 reduces pain and improves sleep and function in diabetic neuropathy patients

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026